Edition:
United States

Rosetta Genomics Ltd (ROSG.OQ)

ROSG.OQ on NASDAQ Stock Exchange Capital Market

0.64USD
30 Nov 2016
Change (% chg)

-- (--)
Prev Close
$0.64
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
17,711
52-wk High
$1.60
52-wk Low
$0.55

ROSG.OQ

Chart for ROSG.OQ

About

Rosetta Genomics Ltd. is engaged in developing and commercializing new diagnostic tests based on various genomics markers, including deoxyribonucleic acid (DNA), micro ribonucleic acid (microRNA) and protein biomarkers and using various technologies, including, Quantitative polymerase chain reaction (qPCR), microarrays, Next... (more)

Overall

Beta: -4.51
Market Cap(Mil.): $15.65
Shares Outstanding(Mil.): 20.87
Dividend: --
Yield (%): --

Financials

  ROSG.OQ Industry Sector
P/E (TTM): -- 42.21 29.87
EPS (TTM): -- -- --
ROI: -- -1.09 14.95
ROE: -- -2.39 16.29

BRIEF-Rosetta Genomics announces pricing of $5 million concurrent registered direct and private placement offering

* Entered into definitive agreements with one institutional healthcare investor to purchase an aggregate of 1.1 million ordinary shares

Nov 23 2016

BRIEF-Rosetta Genomics enters research collaboration using microrna biomarkers to predict response to leading immuno-oncology drug nivolumab in lung cancer patients

* Rosetta genomics enters research collaboration using microrna biomarkers to predict response to leading immuno-oncology drug nivolumab in lung cancer patients Source text for Eikon: Further company coverage:

Nov 21 2016

BRIEF-Rosetta Genomics Ltd - stopped testing of four of its pcr-based gene mutation assays

* Rosetta Genomics Ltd - co has discontinued testing using four of its pcr-based gene mutation assays run out of its lake forest, california facility

Oct 14 2016

BRIEF-Rosetta Genomics fortifies intellectual property portfolio with two new patent allowances

* Rosetta genomics fortifies intellectual property portfolio with two new patent allowances for its novel microrna platform technology

Oct 03 2016

BRIEF-Rosetta Genomics enters distribution agreement for RosettaGX Reveal in Israel with Rhenium

* Rosetta genomics enters distribution agreement for rosettagx reveal(tm) in israel with rhenium

Sep 29 2016

BRIEF-Rosetta Genomics Q2 non-gaap loss per share $0.15 excluding items

* Rosetta genomics reports 2016 second quarter financial results

Sep 26 2016

BRIEF-Rosetta Genomics gets notice of rescission of conditional approval from New York State Department of Health for 4 of co's Allele-specific PCR-based assays

* Got notice of rescission of conditional approval from new york state department of health for 4 of co's Allele-specific PCR-based assays

Aug 22 2016

BRIEF-Rosetta Genomics inks new agreement with Galaxy Health Network

* Rosetta expands managed care coverage with new preferred provider agreement with Galaxy Health Network for entire suite of diagnostic tests and services Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Aug 02 2016

BRIEF-Rosetta Genomics Ltd announces agreement with Preferred Provider Organization

* Rosetta expands managed care coverage with new preferred provider agreement for entire suite of diagnostic tests and services Source text for Eikon: Further company coverage:

Jun 23 2016

Earnings vs. Estimates